The Pharmacogenomics of Bipolar Disorder study (PGBD): Identification of genes for lithium response in a prospective sample

BMC Psychiatry

Volumn 16, Issue 1, 2016, Pages

  Oedegaard, Ketil J ^a,b   Alda, Martin ^c   Anand, Anit ^p   Andreassen, Ole A ^d   Balaraman, Yokesh ^p   Berrettini, Wade H ^e   Bhattacharjee, Abesh ^f,g   Brennand, Kristen J ^h   Burdick, Katherine E ^h   Calabrese, Joseph R ⁱ   Calkin, Cynthia V ^c   Claasen, Ana ^k   Coryell, William H ^j   Craig, David ^k   DeModena, Anna ^f,g   Frye, Mark ^l   Gage, Fred H ^m   Gao, Keming ⁱ   Garnham, Julie ^c   Gershon, Elliot ⁿ   Jakobsen, Petter ^b   Leckband, Susan G ^g   McCarthy, Michael J ^f,g   McInnis, Melvin G ^o   Maihofer, Adam X ^f   Mertens, Jerome ^m   Morken, Gunnar ^r   Nievergelt, Caroline M ^f,g   Nurnberger, John ^p   Pham, Son ^m   Schoeyen, Helle ^s   Shekhtman, Tatyana ^f,g   Shilling, Paul D ^f   Szelinger, Szabolcs ^k   Tarwater, Bruce ^j   Yao, Jun ^m   Zandi, Peter P ^n,q   Kelsoe, John R ^f,g   more..

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c DALHOUSIE UNIVERSITY   (Canada)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF IOWA   (United States)

^k TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^l MAYO CLINIC   (United States)

^m SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

ⁿ UNIVERSITY OF CHICAGO   (United States)

^o UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^p INDIANA UNIVERSITY   (United States)

^q JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^s UNIVERSITY OF BERGEN   (Norway)

more..

Author keywords

Bipolar disorder; GWAS; Lithium; Mood stabilizer; Personalized medicine; Pharmacogenetics; Precision medicine; Prospective trial

Indexed keywords

LITHIUM CARBONATE; MEDROXYPROGESTERONE ACETATE; VALPROIC ACID; ANTIDEPRESSANT AGENT; LITHIUM DERIVATIVE;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSIONS OF SEVERITY SCALE BIPOLAR DISORDER; COGNITION; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISABILITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FATALITY; DSM-IV; FOLLOW UP; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN GENOME; IN VIVO STUDY; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MANIA; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PLURIPOTENT STEM CELL; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; RELAPSE; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDE ATTEMPT; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; MALE; MIDDLE AGED; PHARMACOGENETICS; SECONDARY PREVENTION;

AGED; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW-UP STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; PHARMACOGENETICS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; VALPROIC ACID;

EID: 84965006735     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-016-0732-x     Document Type: Article

References (55)

1. Nierenberg AA, Friedman ES, Bowden CL, Sylvia LG, Thase ME, Ketter T, et al. Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry. 2013;170(1):102-10.
2. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241-51.
3. Mitchell PB, Hadzi-Pavlovic D. John Cade and the discovery of lithium treatment for manic depressive illness. Med J Aust. 1999;171(5):262-4.
4. Severus E, Schaaff N, Moller HJ. State of the art: treatment of bipolar disorders. CNS Neurosci Ther. 2012;18(3):214-8.
5. Fountoulakis KN, Kasper S, Andreassen O, Blier P, Okasha A, Severus E, et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2012;262 Suppl 1:1-48.
6. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002;26(4):530-6.
7. Tohen M, Chengappa KN, Suppes T, Zarate Jr CA, Calabrese JR, Bowden CL, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59(1):62-9.
8. Bowden CL et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400.
9. BALANCE investigators and collaborators, Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385-95.
10. Severus E et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2:15.
11. Rohayem J, Bayle JF, Richa S. Predictors of prophylactic response to lithium. Encéphale. 2008;34(4):394-9.
12. Ebstein R, Belmaker R, Grunhaus L, Rimon R. Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans. Nature. 1976;259:411-3.
13. Belmaker RH. Receptors, adenylate cyclase, depression, and lithium. Biol Psychiatry. 1981;16(4):333-50.
14. Avissar S et al. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature. 1988;331(6155):440-2.
15. Colin SF et al. Chronic lithium regulates the expression of adenylate cyclase and Gi-protein alpha subunit in rat cerebral cortex. Proc Natl Acad Sci USA. 1991;88(23):10634-7.
16. Mork A, Geisler A. Effects of chronic lithium treatment on agonist-enhanced extracellular concentrations of cyclic AMP in the dorsal hippocampus of freely moving rats. J Neurochem. 1995;65(1):134-9.
17. Sherman WR et al. Effects of lithium on phosphoinositide metabolism in vivo. Fed Proc. 1986;45(11):2639-46.
18. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell. 1989;59(3):411-9.
19. Wang HY, Friedman E. Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology (Berl). 1989;99(2):213-8.
20. Friedman E et al. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry. 1993;33(7):520-5.
21. Bebchuk JM et al. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry. 2000;57(1):95-7.
22. Lenox RH et al. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 1992;570(1-2):333-40.
23. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93(16):8455-9.
24. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6(12):1664-8.
25. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A. 1998;95(5):2642-7.
26. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem. 1999;274(10):6039-42.
27. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA. 1999;96(15):8745-50.
28. Bosetti F et al. Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42days of oral lithium administration. Brain Res Bull. 2002;57(2):205-9.
29. McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics. 2007;17(8):605-17.
30. Seelan RS et al. Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells. Neuroscience. 2008;151(4):1184-97.
31. Zhou R et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology. 2009;34(6):1395-405.
32. Chen H et al. MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int J Neuropsychopharmacol. 2009;12(7):975-81.
33. Mendlewicz J, Fieve RR, Stallone F. Relationship between the effectiveness of lithium therapy and family history. Am J Psychiatry. 1973;130(9):1011-3.
34. Grof P et al. Lithium response and genetics of affective disorders. J Affect Disord. 1994;32(2):85-95.
35. Mendlewicz J et al. Lithium accumulation in erythrocytes of manic-depressive patients: an in vivo twin study. Br J Psychiatry. 1978;133:436-44.
36. Grof P et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63(10):942-7.
37. Turecki G et al. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry. 2001;6(5):570-8.
38. Turecki G et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry. 1998;3(6):534-8.
39. Lovlie R et al. The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatr Genet. 2001;11(1):41-3.
40. Serretti A et al. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res. 2000;34(2):89-98.
41. Steen VM et al. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics. 1998;8(3):259-68.
42. Perlis RH et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry. 2009;166(6):718-25.
43. Suppes T et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7):870-86.
44. Spearing MK et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-71.
45. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
46. Young RC et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-35.
47. Altman EG et al. The Clinician-Administered Rating Scale for Mania (CARS-M): development, reliability, and validity. Biol Psychiatry. 1994;36(2):124-34.
48. Trivedi MH et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73-82.
49. Burdick KE et al. Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis. 2006;194(4):255-60.
50. Kieseppa T et al. Memory and verbal learning functions in twins with bipolar-I disorder, and the role of information-processing speed. Psychol Med. 2005;35(2):205-15.
51. Burdick KE et al. COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord. 2007;9(4):370-6.
52. Endicott J et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-6.
53. Lecrubier Y. Clinical utility of venlafaxine in comparison with other antidepressants. Int Clin Psychopharmacol. 1995;10 Suppl 2:29-35.
54. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979;47(2):343-52.
55. Lakatos E. Designing complex group sequential survival trials. Stat Med. 2002;21(14):1969-89.